APS Stock Price, Chart, Stats & News

Aptose Biosciences Inc. is a clinical-stage biotechnology firm dedicated to discovering and advancing personalized therapeutic solutions for challenging oncology cases, primarily within the United States. Its robust pipeline features several key clinical programs: APTO-253, currently in Phase 1a/b trials, targets patients with relapsed or refractory blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS). Another candidate, HM43239, is undergoing Phase 1/2 evaluation for the treatment of relapsed or refractory AML.